What is Positron Emission Tomography (PET)?
Positron emission tomography (PET) is a medical imaging technique involving the use of so-called radiopharmaceuticals, substances that emit radiation that is short-lived and therefore relatively safe to administer to the body. Although the first PET scanner was introduced in 1961, it took 15 more years before radiopharmaceuticals were combined with the technique and revolutionized its potential. The main advantage is that PET (see Figure c) can illustrate physiologic activity-including nutrient metabolism and blood flow of the organ or organs being targeted, whereas CT and MRI scans can only show static images. PET is widely used to diagnose a multitude of conditions, such as heart disease, the spread of cancer, certain forms of infection, brain abnormalities, bone disease, and thyroid disease.
What is combined PET/CT?
Combined PET/CT uses two imaging methods, CT and positron emission tomography (PET), in one procedure. CT is done first to create anatomic pictures of the organs and structures in the body, and then PET is done to create colored pictures that show chemical or other functional changes in tissues.
Different types of positron-emitting (radioactive) substances can be used in PET. Depending on the substance used, different kinds of chemical or functional changes can be imaged. The most common type of PET procedure uses an imaging agent called FDG (a radioactive form of the sugar glucose), which shows the metabolic activity of tissues. Because cancerous tumors are usually more metabolically active than normal tissues, they appear different from other tissues on a PET scan. Other PET imaging agents can provide information about the level of oxygen in a particular tissue, the formation of new blood vessels, the presence of bone growth, or whether tumor cells are actively dividing and growing.
Combining CT and PET may provide a more complete picture of a tumor's location and growth or spread than either test alone. The combined procedure may improve the ability to diagnose cancer, to determine how far a tumor has spread, to plan treatment, and to monitor response to treatment. Combined PET/CT may also reduce the number of additional imaging tests and other procedures a patient needs.
What are nuclear medicine scans used for?
SPECT scans are primarily used to diagnose and track the progression of heart disease, such as blocked coronary arteries. There are also radiotracers to detect disorders in bone, gallbladder disease and intestinal bleeding. SPECT agents have recently become available for aiding in the diagnosis of Parkinson's disease in the brain, and distinguishing this malady from other anatomically-related movement disorders and dementias.
Recently, a PET probe was approved by the FDA to aid in the accurate diagnosis of Alzheimer's disease, which previously could be diagnosed with accuracy only after a patient's death. In the absence of this PET imaging test, Alzheimer's disease can be difficult to distinguish from vascular dementia or other forms of dementia that affect older people.
The major purpose of PET scans is to detect cancer and monitor its progression, response to treatment, and to detect metastases. Glucose utilization depends on the intensity of cellular and tissue activity so it is greatly increased in rapidly dividing cancer cells. In fact, the degree of aggressiveness for most cancers is roughly paralleled by their rate of glucose utilization. In the last 15 years, slightly modified radiolabeled glucose molecules (F-18 labeled deoxyglucose or FDG) have been shown to be the best available tracer for detecting cancer and its metastatic spread in the body.
A combination instrument that produces both PET and CT scans of the same body regions in one examination (PET/CT scanner) has become the primary imaging tool for the staging of most cancers worldwide.